Exosomes in Myocardial Infarction: Therapeutic Potential and Clinical Application

Nian, Wenjian; Fu, Cong

doi:10.1007/s12265-022-10284-3

Cited by 7 publications

(6 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Various drugs as chemotherapeutics and angiogenesis‐stimulators could be loaded on exosomes and delivered different biomedical components to target tissues with great efficacy 168 . As naked exosomes undergo extensive phagocytosis and clearance shortly after transplantation, it has been shown that embedding exosomes on biomaterials such as stents, cardiac patches and cell sheets could profoundly enhance their sustainability and therapeutic efficacy 169 …”

Section: Conclusion and Future Perspectivementioning

confidence: 99%

“…168 As naked exosomes undergo extensive phagocytosis and clearance shortly after transplantation, it has been shown that embedding exosomes on biomaterials such as stents, cardiac patches and cell sheets could profoundly enhance their sustainability and therapeutic efficacy. 169 Tumour-associated exosomes contain considerable angiogenic molecules since angiogenesis is a crucial necessity for tumour development, expansion and far metastasis. It is known that cancerous cell-derived exosomes participate in tumour angiogenesis; thus, neoplastic cells could be suitable sources for angiogenic-exosome isolation.…”

Section: Con Clus I On and Future Per S Pec Tivementioning

confidence: 99%

See 1 more Smart Citation

Exosomes for angiogenesis induction in ischemic disorders

Moeinabadi-Bidgoli

Rezaee

Babajani

et al. 2023

J Cellular Molecular Medi

View full text Add to dashboard Cite

Ischaemic disorders are leading causes of morbidity and mortality worldwide. While the current therapeutic approaches have improved life expectancy and quality of life, they are unable to "cure" ischemic diseases and instate regeneration of damaged tissues. Exosomes are a class of extracellular vesicles with an average size of 100-150 nm, secreted by many cell types and considered a potent factor of cells for parac-

show abstract

Section: Conclusion and Future Perspectivementioning

confidence: 99%

Section: Con Clus I On and Future Per S Pec Tivementioning

confidence: 99%

Exosomes for angiogenesis induction in ischemic disorders

Moeinabadi-Bidgoli

Rezaee

Babajani

et al. 2023

J Cellular Molecular Medi

View full text Add to dashboard Cite

show abstract

“…The development of drug carriers is of great significance for clinical translation, and exosomes and liposomes have shown great potential. First, they have a phospholipid bilayer surface that facilitates phagocytosis by target cells; second, they are structurally stable and have some targeting ability; more importantly, they are highly plastic and can be modified to enhance immune evasion and targeting, making them well suited as drug delivery vehicles ( 131 , 132 ). Excitingly, recently, Li et al.…”

Section: Targeting Strategies Worth Considering For Novel Immunomodul...mentioning

confidence: 99%

Immune cells drive new immunomodulatory therapies for myocardial infarction: From basic to clinical translation

Nian

Huang

2023

Front. Immunol.

Self Cite

View full text Add to dashboard Cite

The high incidence of heart failure secondary to myocardial infarction (MI) has been difficult to effectively address. MI causes strong aseptic inflammation, and infiltration of different immune cells and changes in the local inflammatory microenvironment play a key regulatory role in ventricular remodeling. Therefore, the possibility of improving the prognosis of MI through targeted immunity has been of interest and importance in MI. However, previously developed immune-targeted therapies have not achieved significant success in clinical trials. Here, we propose that the search for therapeutic targets from different immune cells may be more precise and lead to better clinical translation. Specifically, this review summarizes the role and potential therapeutic targets of various immune cells in ventricular remodeling after MI, especially monocytes/macrophages and neutrophils, as a way to demonstrate the importance and potential of immunomodulatory therapies for MI. In addition, we analyze the reasons for the failure of previous immunomodulatory therapies and the issues that need to be addressed, as well as the prospects and targeting strategies of using immune cells to drive novel immunomodulatory therapies, hoping to advance the development of immunomodulatory therapies by providing evidence and new ideas.

show abstract

“…Of note, EVs have been widely implicated in the pathophysiology of various cardiac diseases ( 8 ). For example, it has been suggested that EVs may act as intercellular drivers of cardiac inflammation, leading to cardiac injury and ultimately to HF (reviewed in 9 , 10 ).…”

Section: Introductionmentioning

confidence: 99%

Low extracellular vesicle concentrations predict survival in patients with heart failure

Schöler,

Loosen,

Wirtz

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

BackgroundHeart disease is of worldwide importance due to high morbidity and mortality. Extracellular vesicle (EV) concentration and size represent novel diagnostic and prognostic biomarkers, e.g. in patients with liver cancer, but data on their prognostic relevance in heart disease are lacking. Here, we investigated the role of EV concentration, size and zeta potential in patients with heart disease.MethodsVesicle size distribution, concentration and zeta potential were measured by nanoparticle tracking analysis (NTA) in 28 intensive care unit (ICU) and 20 standard care (SC) patients and 20 healthy controls.ResultsPatients with any disease had a lower zeta potential compared to the healthy controls. Vesicle size (X50) was significantly higher in ICU patients (245 nm) with heart disease as compared to those patients with heart disease receiving standard care (195 nm), or healthy controls (215 nm) (p = 0.001). Notably, EV concentration was lower in ICU patients with heart disease (4.68 × 1010 particles/ml) compared to SC patients with heart disease (7,62 × 1010 particles/ml) and healthy controls (1.50 × 1011 particles/ml) (p = 0.002). Extracellular vesicle concentration is prognostic for overall survival in patients with heart disease. Overall survival is significantly reduced when the vesicle concentration is below 5.55 × 1010 particles/ml. Median overall survival was only 140 days in patients with vesicle concentrations below 5.55 × 1010 particles/ml compared to 211 days in patients with vesicle concentrations above 5.55 × 1010 particles/ml (p = 0.032).SummaryConcentration of EVs is a novel prognostic marker in ICU and SC patients with heart disease.

show abstract

Exosomes in Myocardial Infarction: Therapeutic Potential and Clinical Application

Cited by 7 publications

References 67 publications

Exosomes for angiogenesis induction in ischemic disorders

Exosomes for angiogenesis induction in ischemic disorders

Immune cells drive new immunomodulatory therapies for myocardial infarction: From basic to clinical translation

Low extracellular vesicle concentrations predict survival in patients with heart failure

Contact Info

Product

Resources

About